Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchard Therapeutics Plc ADR (NQ: ORTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Orchard Therapeutics Plc ADR

< Previous 1 2 3 4 5 Next >
Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Is Meiwu Technology (WNW) Stock Up 70% Today?
Meiwu Technology is on the move Thursday with heavy trading of WNW stock despite lack of news or filings to explain the rally! 
Via InvestorPlace
Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today?
Orchard Therapeutics stock is rising higher on Thursday as Kyowa Kirin agrees to acquire ORTX shares for $16 each in a $387.4 million deal. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
Via InvestorPlace
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Why Gene Therapy Company Orchard Therapeutics Stock Is Skyrocketing Today?
Gene therapy company Orchard Therapeutics Plc (NASDAQ: ORTX) shares are trading higher after it agreed to be acquired by Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, for... 
Via Benzinga
Kyowa Kirin to Acquire Orchard Therapeutics
From Orchard Therapeutics (Europe) Limited; Kyowa Kirin Co., Ltd.
Via GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Why Orchard Therapeutics Stock Is Trading Higher Today
Orchard Therapeutics Inc (NASDAQ: ORTX) announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic  
Via Benzinga
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday
B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%... 
Via Benzinga
Orchard Therapeutics Completes ADS Ratio Change
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Proposed ADS Ratio Change
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.